586 related articles for article (PubMed ID: 32385107)
1. Vestigial-like family member 3 (VGLL3), a cofactor for TEAD transcription factors, promotes cancer cell proliferation by activating the Hippo pathway.
Hori N; Okada K; Takakura Y; Takano H; Yamaguchi N; Yamaguchi N
J Biol Chem; 2020 Jun; 295(26):8798-8807. PubMed ID: 32385107
[TBL] [Abstract][Full Text] [Related]
2. Nuclear phosphoinositide signaling promotes YAP/TAZ-TEAD transcriptional activity in breast cancer.
Jung O; Baek MJ; Wooldrik C; Johnson KR; Fisher KW; Lou J; Ricks TJ; Wen T; Best MD; Cryns VL; Anderson RA; Choi S
EMBO J; 2024 May; 43(9):1740-1769. PubMed ID: 38565949
[TBL] [Abstract][Full Text] [Related]
3. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation.
Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL
Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853
[TBL] [Abstract][Full Text] [Related]
4. Hippo signaling effectors YAP and TAZ induce Epstein-Barr Virus (EBV) lytic reactivation through TEADs in epithelial cells.
Van Sciver N; Ohashi M; Pauly NP; Bristol JA; Nelson SE; Johannsen EC; Kenney SC
PLoS Pathog; 2021 Aug; 17(8):e1009783. PubMed ID: 34339458
[TBL] [Abstract][Full Text] [Related]
5. Regulation of the Hippo Pathway Transcription Factor TEAD.
Lin KC; Park HW; Guan KL
Trends Biochem Sci; 2017 Nov; 42(11):862-872. PubMed ID: 28964625
[TBL] [Abstract][Full Text] [Related]
6. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
Jang JW; Kim MK; Bae SC
Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
[TBL] [Abstract][Full Text] [Related]
7. A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis.
Moroishi T; Park HW; Qin B; Chen Q; Meng Z; Plouffe SW; Taniguchi K; Yu FX; Karin M; Pan D; Guan KL
Genes Dev; 2015 Jun; 29(12):1271-84. PubMed ID: 26109050
[TBL] [Abstract][Full Text] [Related]
8. VGLL3 confers slow-twitch muscle differentiation via PGC-1α expression in C2C12 myocytes.
Takakura Y; Suzuki T; Hirai N; Araki T; Ohishi M; Sato H; Yamaguchi N; Takano H; Yamaguchi N
Biochem Biophys Res Commun; 2023 Aug; 669():30-37. PubMed ID: 37262950
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a cryptic site at the interface 2 of TEAD - Towards a new family of YAP/TAZ-TEAD inhibitors.
Sturbaut M; Bailly F; Coevoet M; Sileo P; Pugniere M; Liberelle M; Magnez R; Thuru X; Chartier-Harlin MC; Melnyk P; Gelin M; Allemand F; Guichou JF; Cotelle P
Eur J Med Chem; 2021 Dec; 226():113835. PubMed ID: 34509860
[TBL] [Abstract][Full Text] [Related]
10. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
Crawford JJ; Bronner SM; Zbieg JR
Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
[No Abstract] [Full Text] [Related]
11. Vestigial-like family member 3 stimulates cell motility by inducing high-mobility group AT-hook 2 expression in cancer cells.
Hori N; Takakura Y; Sugino A; Iwasawa S; Nomizo K; Yamaguchi N; Takano H; Yamaguchi N
J Cell Mol Med; 2022 May; 26(9):2686-2697. PubMed ID: 35366053
[TBL] [Abstract][Full Text] [Related]
12. NPHP4, a cilia-associated protein, negatively regulates the Hippo pathway.
Habbig S; Bartram MP; Müller RU; Schwarz R; Andriopoulos N; Chen S; Sägmüller JG; Hoehne M; Burst V; Liebau MC; Reinhardt HC; Benzing T; Schermer B
J Cell Biol; 2011 May; 193(4):633-42. PubMed ID: 21555462
[TBL] [Abstract][Full Text] [Related]
13. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).
Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B
J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650
[TBL] [Abstract][Full Text] [Related]
14. VGLL3 operates via TEAD1, TEAD3 and TEAD4 to influence myogenesis in skeletal muscle.
Figeac N; Mohamed AD; Sun C; Schönfelder M; Matallanas D; Garcia-Munoz A; Missiaglia E; Collie-Duguid E; De Mello V; Pobbati AV; Pruller J; Jaka O; Harridge SDR; Hong W; Shipley J; Vargesson N; Zammit PS; Wackerhage H
J Cell Sci; 2019 Jul; 132(13):. PubMed ID: 31138678
[TBL] [Abstract][Full Text] [Related]
15. Ski regulates Hippo and TAZ signaling to suppress breast cancer progression.
Rashidian J; Le Scolan E; Ji X; Zhu Q; Mulvihill MM; Nomura D; Luo K
Sci Signal; 2015 Feb; 8(363):ra14. PubMed ID: 25670202
[TBL] [Abstract][Full Text] [Related]
16. Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy.
Juan WC; Hong W
Genes (Basel); 2016 Aug; 7(9):. PubMed ID: 27589805
[TBL] [Abstract][Full Text] [Related]
17. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein.
Zhao B; Li L; Lu Q; Wang LH; Liu CY; Lei Q; Guan KL
Genes Dev; 2011 Jan; 25(1):51-63. PubMed ID: 21205866
[TBL] [Abstract][Full Text] [Related]
18. Sphingosylphosphorylcholine regulates the Hippo signaling pathway in a dual manner.
Kemppainen K; Wentus N; Lassila T; Laiho A; Törnquist K
Cell Signal; 2016 Dec; 28(12):1894-1903. PubMed ID: 27634386
[TBL] [Abstract][Full Text] [Related]
19. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
[TBL] [Abstract][Full Text] [Related]
20. A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
Hillen H; Candi A; Vanderhoydonck B; Kowalczyk W; Sansores-Garcia L; Kesikiadou EC; Van Huffel L; Spiessens L; Nijs M; Soons E; Haeck W; Klaassen H; Smets W; Spieser SA; Marchand A; Chaltin P; Ciesielski F; Debaene F; Chen L; Kamal A; Gwaltney SL; Versele M; Halder GA
Mol Cancer Ther; 2024 Jan; 23(1):3-13. PubMed ID: 37748190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
